China's Sino Biopharmaceutical up on products' inclusion in National Drug Catalogue

Sino Biopharmaceutical

14/12/2023 03:20

** Shares of Sino Biopharmaceutical Ltd  1177.HK  rise 6.9%
to HK$3.56, their highest since Dec. 5
    ** Stock on track for the third straight session of gain and
biggest one-day pct rise since Nov. 3, if gains hold
    ** Co says seven of its products have been included in the
National Drug Catalogue for Basic Medical Insurance, WorkRelated
Injury Insurance and Maternity Insurance (2023), which are
expected to be important products contributing to its revenue
growth in 2024
    ** Co says application for marketing of its injection for
hemophiliacs patients has been filed with and accepted by the
National Medical Products Administration of China 
    ** The Hang Seng Commerce & Industry Index  .HSNC  climbs
1.2%, healthcare index  .HSCIH  rises 2.4%, and Hang Seng Index
 .HSI  adds 1.3%
    ** Stock down 24.5% YTD 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))